Companies · Pharma

Mimosa Therapeutics, A Public Benefit Corp

ALAMEDA · Pharma · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Mimosa Therapeutics, A Public Benefit Corp — recommendation, valuation, rhythm, risks.
$1.3M
Total raised · real
2
Rounds
0.5×
Latest step-up
Top 63%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Thu Jul 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Mimosa Therapeutics, A Public Benefit Corp looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.78× the median modeled value of Pre-Seed Pharma companies in 2019–2021 (20 peers) — value vs value, same stage and era.
  • Within the normal band (78% of peer median) for its niche.
Dormant
  • Last raise 5.0 yr ago; this sector typically re-raises about every 16 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharma

Mimosa Therapeutics, A Public Benefit Corp is one of 310 Pharma companies tracked from ALAMEDA. By capital raised it ranks in the long tail (ahead of 38% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 504
Reg D exemption
5
Investors (latest)
2020
Year incorporated
2021-07-01
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2021-02-09 Raised $865K (real) Modeled valuation $29M (est)$865K$29MPre-Seed2021Pre-Seed · 2021-07-01 Raised $400K (real) Modeled valuation $11M (est)$400K$11MPre-Seed2021+$400KCumulative $1.3M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$865K · 2021
Pre-Seed extension$400K · 2021

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$10.5M
Base estimate est.
$224K
Conservative case
$88.2M
Upside case
$2.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $28.6M · 2021-02-092021Pre-Seed · modeled $10.5M · 2021-07-012021
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
5.0 yr
Elapsed time used
5.0 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
5 mo
Avg between rounds
$3.3M/yr
Capital velocity
5.4 yr
On record since
2021
First round
2
Rounds on file
How it compares to the market

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.2× of median
This company$1.3M
Sector median$6.4M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.3× above median
This company$400K
Sector median$307K
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$10.5M
Sector median$62.5M

Raised more than 38% of sector peers (real $). Modeled value above 35% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #13 of 20.

This companyCohort peer
$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Jupiter Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $47.3M (est)Tavros Therapeutics, Inc. · Pre-Seed Raised $1000K · modeled $47.3M (est)Kalytera Therapeutics, Inc. · Pre-Seed Raised $2.2M · modeled $35.9M (est)Veterinary Radiation Oncology of the Chesapeake, LLC · Pre-Seed Raised $925K · modeled $29.6M (est)Chamishi Therapeutics, Inc. · Pre-Seed Raised $490K · modeled $23.2M (est)Ikaika Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $22.5M (est)Organoid Therapeutics, Inc. · Pre-Seed Raised $445K · modeled $21.0M (est)Mindset Pharma Inc. · Pre-Seed Raised $694K · modeled $20.7M (est)Neurexis Therapeutics, Inc. · Pre-Seed Raised $500K · modeled $16.1M (est)Hyka Therapeutics Inc. · Pre-Seed Raised $307K · modeled $14.5M (est)Chekkit · Pre-Seed Raised $500K · modeled $12.3M (est)Naturomed Therapeutics, Ltd. · Pre-Seed Raised $585K · modeled $12.0M (est)Mimosa Therapeutics, A Public Benefit Corp (this company) Raised $1.3M · modeled $10.5M (est)Mimosa Therapeutics, A Public Benefit Corp
CompanyStageRaised · realValue · estvs peer med.
Jupiter Therapeutics, Inc.Pre-Seed$1.0M$47.3M3.52×
Tavros Therapeutics, Inc.Pre-Seed$1000K$47.3M3.52×
Kalytera Therapeutics, Inc.Pre-Seed$2.2M$35.9M2.67×
Veterinary Radiation Oncology of the Chesapeake, LLCPre-Seed$925K$29.6M2.20×
Chamishi Therapeutics, Inc.Pre-Seed$490K$23.2M1.73×
Ikaika Therapeutics, Inc.Pre-Seed$1.0M$22.5M1.67×
Organoid Therapeutics, Inc.Pre-Seed$445K$21.0M1.57×
Mindset Pharma Inc.Pre-Seed$694K$20.7M1.54×
Neurexis Therapeutics, Inc.Pre-Seed$500K$16.1M1.20×
Hyka Therapeutics Inc.Pre-Seed$307K$14.5M1.08×
ChekkitPre-Seed$500K$12.3M0.92×
Naturomed Therapeutics, Ltd.Pre-Seed$585K$12.0M0.90×
Mimosa Therapeutics, A Public Benefit Corp this companyPre-Seed$1.3M$10.5M0.78×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$865K2021-02-09$4.8M$28.6M90%
Pre-Seed$400K2021-07-01$2.2M$10.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$865K2021-02-09
    • First recorded raise — entered as Pre-Seed.
    • 4 investors on this round.
  2. Pre-Seed$400K2021-07-01
    • Came back fast: 5 mo vs the ~16 mo sector norm.
    • Round 2.2× smaller than the prior — bridge or down round.
    • Switched to Rule 504 (was Rule 506(b)).
    • 5 investors on this round.
Intelligence
2021 ~Q4
Modeled next raise · ~5mo cadence
$400K
Modeled next size est.range $400K$640K
0.5×
Last step-up
$3.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert Stanley1 other2021-02
Amanda Feilding2021-02
James Keim2021-02
Stephen Apkon2021-02
Registry & provenance

Mimosa Therapeutics, A Public Benefit Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1844977
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Acanna Therapeutics, Inc.PharmaPre-Seed$1.0M$16.1Msame sector · same stage
Ikaika Therapeutics, Inc.PharmaPre-Seed$1.0M$22.5Msame sector · same stage
Jupiter Therapeutics, Inc.PharmaPre-Seed$1.0M$47.3Msame sector · same stage
Tavros Therapeutics, Inc.PharmaPre-Seed$1000K$47.3Msame sector · same stage
vivo-TIL Therapeutics, IncPharmaPre-Seed$990K$46.8Msame sector · same stage
UVLrx Therapeutics, Inc.PharmaPre-Seed$980K$9.7Msame sector · same stage
Protibea Therapeutics, Inc.PharmaPre-Seed$970K$481Ksame sector · same stage
JSK Therapeutics, Inc.PharmaPre-Seed$963K$45.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Mizar Therapeutics, Inc.PharmaPre-Seed$1.4M81%
Mirador Therapeutics, Inc.PharmaSeries D+$4.0B77%
PiVista Therapeutics, Inc.PharmaPre-Seed$2.5M77%
FloSpine Holdings, Inc.Other Health CarePre-Seed$409K77%
Cyana Therapeutics, LLCPharmaPre-Seed$300K76%
Synereca Pharmaceuticals, Inc.Biotech / PharmaPre-Seed$30.7M76%
Cyrano Therapeutics, Inc.PharmaSeries A$108.4M76%
Convelo Therapeutics, Inc.PharmaSeries A$113.3M75%
Frequently asked
How much funding has Mimosa Therapeutics, A Public Benefit Corp raised?
Mimosa Therapeutics, A Public Benefit Corp has raised approximately $1.3M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Mimosa Therapeutics, A Public Benefit Corp's estimated valuation?
Provath's modeled valuation for Mimosa Therapeutics, A Public Benefit Corp is approximately $10.5M (modeled range $224K–$88.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Mimosa Therapeutics, A Public Benefit Corp at?
Mimosa Therapeutics, A Public Benefit Corp's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Thu Jul 01.
What does Mimosa Therapeutics, A Public Benefit Corp do and where is it based?
Mimosa Therapeutics, A Public Benefit Corp operates in the Pharma sector, based in ALAMEDA.
Explore related

See where Mimosa Therapeutics, A Public Benefit Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Mimosa Therapeutics, A Public Benefit Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.